Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments (2019 - 2025)

Crinetics Pharmaceuticals (CRNX) has 7 years of Change in Acquisitions & Divestments data on record, last reported at $271.2 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 47.42% year-over-year to $271.2 million; the TTM value through Dec 2025 reached $1.2 billion, up 105.64%, while the annual FY2025 figure was $1.2 billion, 105.64% up from the prior year.
  • Change in Acquisitions & Divestments reached $271.2 million in Q4 2025 per CRNX's latest filing, down from $382.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $382.4 million in Q3 2025 and bottomed at $244000.0 in Q4 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $116.2 million, with a median of $87.3 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 98.12% in 2021, then skyrocketed 28870.49% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $244000.0 in 2021, then surged by 28870.49% to $70.7 million in 2022, then increased by 22.62% to $86.7 million in 2023, then soared by 112.24% to $184.0 million in 2024, then soared by 47.42% to $271.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $271.2 million in Q4 2025, $382.4 million in Q3 2025, and $224.0 million in Q2 2025.